Miraculins Announces National Accreditation of Pharmacist Education Program on Cardiovascular Risk Assessment with Focus on

Miraculins Announces National Accreditation of Pharmacist Education Program on 
Cardiovascular Risk Assessment with Focus on Skin
Cholesterol 
WINNIPEG, MANITOBA -- (Marketwire) -- 03/15/13 -- Miraculins Inc.
(TSX VENTURE:MOM), a medical diagnostic company focused on acquiring,
developing and commercializing diagnostic tests and risk assessment
technologies for unmet clinical needs, in conjunction with Pear
Healthcare Solutions, today announces the accreditation of a national
program for pharmacists with the course name Cardiovascular Risk
Assessment: Focus on Non-Invasive Skin Cholesterol Screening.  
All Canadian pharmacists are under obligation by their respective
provincial authorities to engage in lifelong learning and competency
enhancements that supports optimal, patient centered, outcome focused
care through medication management and effective pharmacy practice.
With the national accreditation of the cardiovascular (CV) risk
assessment education program, Canadian pharmacists can now earn
credits to meet this requirement by learning about the benefits of
providing CV risk assessment onsite, and skin cholesterol's role
within that environment as an emerging biomarker in coronary artery
disease risk assessment and screening. 
The three modules of the program available at www.healthelearning.ca
include: 


 
Module 1 -    Cardiovascular Risk Assessment Background        (0.50 CEU)   
                                                                            
Module 2 -    Non-invasive Skin Cholesterol Testing as an      (0.50 CEU)   
              Option for CV Risk Assessment                                 
                                                                            
Module 3 -    Communication and Action Plans                   (0.50 CEU)   

 
"The retail pharmacy segment is an important distribution channel for
the PreVu(R) Non-Invasive Skin Cholesterol Point of Care (POC) Test,"
said Christopher J. Moreau, President and CEO of Miraculins Inc. "The
newly accredited program for cardiovascular risk assessment is
another important step forward in educating pharmacists about the
science and biology of skin cholesterol and its role in coronary
artery disease risk assessment. This will provide a very important
educational foundation for pharmacists as we work in parallel towards
offering the PreVu POC Test to all potentially at-risk Canadians
through additional national, regional and independent pharmacy
locations." 
About the PreVu Non-Invasive Skin Cholesterol Test  
The PreVu(R) Non-Invasive Skin Cholesterol Point of Care (POC) Test
is a non-invasive, risk assessment technology designed to measure
skin cholesterol - an emerging biomarker in helping to assess risk of
coronary artery disease ("CAD"). The PreVu(R) POC Test is completely
painless, non-invasive, involves no blood draw or needles, and
requires no overnight fasting. The test is conducted on the palm of
the hand in less than 5 minutes with results being immediately
available, facilitating point of care consultation and a next steps
discussion. Skin cholesterol is the cholesterol that has been
deposited and diffused into tissue, as opposed to freely circulating
in the bloodstream, and the skin contains approximately 11% of all
the cholesterol found in the human body, by weight. Elevated skin
cholesterol has been shown in clinical studies to be strongly
associated with an increased risk of significant CAD as measured by
treadmill stress testing and coronary angiography, as well as
measured by testing for coronary calcium, carotid artery thickening,
and carotid artery plaque. The PreVu POC Test does not diagnose the
presence or absence of CAD, but helps to identify patients who may be
at higher, hidden risk for CAD by measuring their levels of skin
cholesterol. The PreVu POC Test is not a substitute or replacement
for blood serum cholesterol testing. For more information visit
www.prevu.com. 
About Pear Healthcare Solutions 
Pear Healthcare Solutions is a privately held company specializing in
the development and implementation of programs to address the
evolving needs of pharmacists in their expanding role of providing
healthcare and disease management services. Pear Healthcare Solutions
offers a number of innovative medical devices and professional
education programs that help pharmacies connect with their patients,
improving their health and wellness. Pear provides distribution,
training and support/education services. For more information visit
www.pearhealthcare.com. 
About Miraculins Inc. 
Miraculins is a medical diagnostic company focused on acquiring,
developing and commercializing non-invasive tests for unmet clinical
needs. A significant number of promising diagnostic opportunities
remain un-commercialized because of the sizable gap between the
discovery stage, when research institutions are typically involved,
and the commercialization stage, when the larger commercial
enterprises become interested. Miraculins has direct experience in
bridging this gap. The Company's PreVu(R) technology is a
revolutionary new coronary artery disease risk assessment technology
that measures cholesterol levels in a patient's skin non-invasively,
painlessly and without the need for fasting. Miraculins is also
advancing a suite of biomarkers to aid in the early detection of the
devastating disease of pregnancy known as preeclampsia. The Company's
preeclampsia program is partnered with Alere Inc., one of the world's
largest diagnostic companies. For more information visit
www.miraculins.com. 
Caution Regarding Forward-Looking Information 
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable Canadian
provincial securities legislation (collectively, "forward-looking
statements"). These forward-looking statements relate to, among other
things, our objectives, goals, targets, strategies, intentions,
plans, beliefs, estimates and outlook, including, without limitation,
our anticipated future operating results, and can, in some cases, be
identified by the use of words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and other similar
expressions. In addition, any statements that refer to expectations,
projections or other characterizations of future events or
circumstances are forward-looking statements. 
These statements reflect management's current beliefs and are based
on information currently available to management. Certain material
factors or assumptions are applied in making forward-looking
statements, and actual results may differ materially from those
expressed or implied in such statements. Important factors that could
cause actual results to differ materially from these expectations
include, among other things: Miraculins' early stage of development,
lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development,
rapid technological change, uncertainties related to forecasts,
competition, potential product liability, additional financing
requirements and access to capital, unproven markets, supply of raw
materials, income tax matters, management of growth, partnerships for
development and commercialization of technology, effects of insurers'
willingness to pay for products, system failures, dependence on key
personnel, foreign currency risk, risks related to regulatory matters
and risks related to intellectual property and other risks detailed
from time to time in Miraculins' filings with Canadian securities
regulatory authorities, as well as Miraculins' ability to anticipate
and manage the risks associated with the foregoing. Additional
information about these factors and about the material factors or
assumptions underlying such forward-looking statements may be found
in the body of this news release. Miraculins cautions that the
foregoing list of important factors that may affect future results is
not exhaustive. When relying on Miraculins' forward-looking
statements to make decisions with respect to Miraculins investors and
others should carefully consider the foregoing factors and other
uncertainties and potential events. 
These risks and uncertainties should be considered carefully and
prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management
believes to be reasonable assumptions, Miraculins cannot provide
assurance that actual results will be consistent with these
forward-looking statements. Miraculins undertakes no obligation to
update or revise any forward-looking statement.  
PreVu(R) is a registered trademark of Miraculins Inc. All Rights
Reserved. 2013. 
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release. 
Contacts:
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1596 (FAX)
info@miraculins.com
www.miraculins.com
 
 
Press spacebar to pause and continue. Press esc to stop.